接种Comirnaty©疫苗后的过敏反应病例和促进过敏流行对国家疫苗接种规划不利——流行病学专家小组和国家过敏症顾问的建议是不现实的

IF 0.2 Q4 ALLERGY
M. Kurek
{"title":"接种Comirnaty©疫苗后的过敏反应病例和促进过敏流行对国家疫苗接种规划不利——流行病学专家小组和国家过敏症顾问的建议是不现实的","authors":"M. Kurek","doi":"10.5114/PJA.2021.104654","DOIUrl":null,"url":null,"abstract":"No cases of anaphylaxis were registered In the clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines In December mass vaccination programs have been implemented in the United Kingdom and in the United States In the U K two anaphylactic episodes were registered after the first dose of the mRNA Pfizer vaccine which were two women with known food and drug allergies At least a dozen episodes have been reported in the USA It was also speculated that the incidence of anaphylaxis due to usage of the Pfizer vaccine, might be 10-times higher, as the incidence with all other vaccines Anaphylactic episodes related to mRNA Moderna vaccine seems to be rarer In response to the first two episodes, related to the Pfizer vaccine, the MHRA excluded any person with an history of anaphylaxis after food, drug, or vaccine In the USA, the CDC excluded any person who has a history of a severe or immediate allergic reaction associated with any of the vaccine components, such as polyethylene glycol (PEG) and other glycols We believe the reasoning behind that this is too vague and these precautions are too extreme Thy only security measure that should be applied is post vaccinal surveillance on global, national and individual level Appropriate reference points are accessible These are as follow: revised nomenclature for allergy for global use, as well, definitions and management principles of adverse drug reactions In Poland vaccination program started at the end of December On December 26, recommendations of our Epidemiology Experts-team appeared Unfortunately these are a just compilation of MHRA and CDC precautions Recommendations of the National Consultant in Allergology appeared on December 28 Instead exclusion of every person with an history of anaphylaxis after food, drug, or vaccine, a special caution is recommended after every episode It is required that an allergist detects sensi-tisations to all ingredients of the Comirnaty© vaccine In fact this is unrealistic In Poland these substances are not accessible for the routine diagnostic Unfortunately the global unified terminology for allergy and adverse drug reactions is rarely respected by academicians, and by allergists The real prevalence of clinically relevant phenomenon of individual hypersensitivity, allergic and nonallergic alike, remains unclear or misinterpreted This disturbs the doctor’ s logical reasoning and increase the patient`s fears","PeriodicalId":7469,"journal":{"name":"Alergologia Polska - Polish Journal of Allergology","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Cases of anaphylaxis after the Comirnaty© vaccine and promotion \\nof allergy epidemic are unfavourable for the National Vaccination \\nProgramme – recommendations of the epidemiology experts-team and of the national consultant in allerglogy are unrealistic\",\"authors\":\"M. Kurek\",\"doi\":\"10.5114/PJA.2021.104654\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"No cases of anaphylaxis were registered In the clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines In December mass vaccination programs have been implemented in the United Kingdom and in the United States In the U K two anaphylactic episodes were registered after the first dose of the mRNA Pfizer vaccine which were two women with known food and drug allergies At least a dozen episodes have been reported in the USA It was also speculated that the incidence of anaphylaxis due to usage of the Pfizer vaccine, might be 10-times higher, as the incidence with all other vaccines Anaphylactic episodes related to mRNA Moderna vaccine seems to be rarer In response to the first two episodes, related to the Pfizer vaccine, the MHRA excluded any person with an history of anaphylaxis after food, drug, or vaccine In the USA, the CDC excluded any person who has a history of a severe or immediate allergic reaction associated with any of the vaccine components, such as polyethylene glycol (PEG) and other glycols We believe the reasoning behind that this is too vague and these precautions are too extreme Thy only security measure that should be applied is post vaccinal surveillance on global, national and individual level Appropriate reference points are accessible These are as follow: revised nomenclature for allergy for global use, as well, definitions and management principles of adverse drug reactions In Poland vaccination program started at the end of December On December 26, recommendations of our Epidemiology Experts-team appeared Unfortunately these are a just compilation of MHRA and CDC precautions Recommendations of the National Consultant in Allergology appeared on December 28 Instead exclusion of every person with an history of anaphylaxis after food, drug, or vaccine, a special caution is recommended after every episode It is required that an allergist detects sensi-tisations to all ingredients of the Comirnaty© vaccine In fact this is unrealistic In Poland these substances are not accessible for the routine diagnostic Unfortunately the global unified terminology for allergy and adverse drug reactions is rarely respected by academicians, and by allergists The real prevalence of clinically relevant phenomenon of individual hypersensitivity, allergic and nonallergic alike, remains unclear or misinterpreted This disturbs the doctor’ s logical reasoning and increase the patient`s fears\",\"PeriodicalId\":7469,\"journal\":{\"name\":\"Alergologia Polska - Polish Journal of Allergology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alergologia Polska - Polish Journal of Allergology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/PJA.2021.104654\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alergologia Polska - Polish Journal of Allergology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/PJA.2021.104654","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 1

摘要

没有过敏反应病例的临床试验注册Pfizer-BioNTech 12月和现代化mRNA疫苗大规模疫苗接种程序实现了在英国和美国在美国K两个过敏发作后注册的第一剂量mRNA辉瑞疫苗被两个女人与已知的食品和药物过敏至少十几集已报告在美国也是猜测,过敏反应的发生率因对于与辉瑞疫苗相关的前两次过敏事件,MHRA排除了任何在食物、药物或疫苗后有过敏史的人。在美国,CDC排除了任何有与任何疫苗成分相关的严重或立即过敏反应史的人。我们认为,这种说法背后的理由过于模糊,这些预防措施也过于极端。唯一应该采取的安全措施是在全球、国家和个人层面进行疫苗后监测,可获得适当的参考点如下:在波兰,疫苗接种计划于12月底启动。12月26日,我们的流行病学专家小组提出了建议。不幸的是,这些只是MHRA和CDC预防措施的汇编。国家过敏症顾问的建议于12月28日提出,而不是排除所有有食物,药物,或疫苗,每次发作后建议特别注意,要求过敏症专科医生检测对Comirnaty©疫苗所有成分的致敏性,事实上这是不现实的,在波兰,这些物质无法用于常规诊断。不幸的是,过敏和药物不良反应的全球统一术语很少受到学者和过敏症专科医生的尊重。这扰乱了医生的逻辑推理,增加了病人的恐惧
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cases of anaphylaxis after the Comirnaty© vaccine and promotion of allergy epidemic are unfavourable for the National Vaccination Programme – recommendations of the epidemiology experts-team and of the national consultant in allerglogy are unrealistic
No cases of anaphylaxis were registered In the clinical trials of the Pfizer-BioNTech and Moderna mRNA vaccines In December mass vaccination programs have been implemented in the United Kingdom and in the United States In the U K two anaphylactic episodes were registered after the first dose of the mRNA Pfizer vaccine which were two women with known food and drug allergies At least a dozen episodes have been reported in the USA It was also speculated that the incidence of anaphylaxis due to usage of the Pfizer vaccine, might be 10-times higher, as the incidence with all other vaccines Anaphylactic episodes related to mRNA Moderna vaccine seems to be rarer In response to the first two episodes, related to the Pfizer vaccine, the MHRA excluded any person with an history of anaphylaxis after food, drug, or vaccine In the USA, the CDC excluded any person who has a history of a severe or immediate allergic reaction associated with any of the vaccine components, such as polyethylene glycol (PEG) and other glycols We believe the reasoning behind that this is too vague and these precautions are too extreme Thy only security measure that should be applied is post vaccinal surveillance on global, national and individual level Appropriate reference points are accessible These are as follow: revised nomenclature for allergy for global use, as well, definitions and management principles of adverse drug reactions In Poland vaccination program started at the end of December On December 26, recommendations of our Epidemiology Experts-team appeared Unfortunately these are a just compilation of MHRA and CDC precautions Recommendations of the National Consultant in Allergology appeared on December 28 Instead exclusion of every person with an history of anaphylaxis after food, drug, or vaccine, a special caution is recommended after every episode It is required that an allergist detects sensi-tisations to all ingredients of the Comirnaty© vaccine In fact this is unrealistic In Poland these substances are not accessible for the routine diagnostic Unfortunately the global unified terminology for allergy and adverse drug reactions is rarely respected by academicians, and by allergists The real prevalence of clinically relevant phenomenon of individual hypersensitivity, allergic and nonallergic alike, remains unclear or misinterpreted This disturbs the doctor’ s logical reasoning and increase the patient`s fears
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
50.00%
发文量
18
期刊介绍: Alergologia Polska - Polish Journal of Allergology is aimed mainly at allergologists, but also medical doctors working in related fields, such as otolaryngology, pulmonology, and dermatology. The main goal of the journal is to ensure rapid publication of important research papers and interesting case studies from the following areas: allergology, diagnostics, therapy of allergic diseases, in particular in the area of immunotherapy, rhinitis, asthma. The Editorial Board accepts for publication original papers, case studies and letters to the Editor. We also publish review articles (both commissioned and those agreed upon with the Editor-in-Chief), articles dealing with standards of medical practice, as well as special issues. The journal is published quarterly. We guarantee short review times (up to two weeks) and immediate publication on-line upon Editor acceptance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信